Clinical Trials Browser

Phase 1/2 × NIH × cixutumumab × Clear all

NCT00617708 2022-02-08

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 1/2 Completed

134 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01026623 2019-06-17

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Phase 1/2 Completed

16 enrolled 12 charts

Prostatic Neoplasms

NCT00699491 2018-06-13

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Completed

48 enrolled 14 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00778167 2014-05-21

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 1/2 Completed

18 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung